218 related articles for article (PubMed ID: 33044009)
21. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study
Gelderblom H; Judson IR; Benson C; Merimsky O; Grignani G; Katz D; Freivogel KW; Stein D; Jobanputra M; Mungul A; Manson SC; Sanfilippo R
Acta Oncol; 2017 Dec; 56(12):1769-1775. PubMed ID: 28723233
[TBL] [Abstract][Full Text] [Related]
22. Intimal Sarcoma of the Pulmonary Artery Treated with Pazopanib.
Funatsu Y; Hirayama M; Shiraishi J; Asakura T; Wakaki M; Yamada E; Fujimoto K; Satomi R; Inaki S; Murata Y; Oyamada Y
Intern Med; 2016; 55(16):2197-202. PubMed ID: 27522994
[TBL] [Abstract][Full Text] [Related]
23. Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.
Kim HJ; Kim Y; Lee SJ; Lee J; Park SH
J Gynecol Oncol; 2018 Jan; 29(1):e3. PubMed ID: 29185261
[TBL] [Abstract][Full Text] [Related]
24. Vastus lateralis myocutaneous flap for ischial skin wound following the treatment of epithelioid sarcoma using pazopanib.
Tsujii M; Matsumine A; Nakamura T; Satonaka H; Sudo A
J Wound Care; 2020 Jun; 29(6):335-339. PubMed ID: 32530777
[TBL] [Abstract][Full Text] [Related]
25. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world.
Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B
Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596
[TBL] [Abstract][Full Text] [Related]
26. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
[TBL] [Abstract][Full Text] [Related]
28. Balancing Prolonged Survival with QoL Using Low-dose Pazopanib Maintenance: A Comparison with the PALETTE Study.
Abe K; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Inatani H; Higuchi T; Taniguchi Y; Tsuchiya H
Anticancer Res; 2016 Jun; 36(6):2893-7. PubMed ID: 27272802
[TBL] [Abstract][Full Text] [Related]
29. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
Glade Bender JL; Lee A; Reid JM; Baruchel S; Roberts T; Voss SD; Wu B; Ahern CH; Ingle AM; Harris P; Weigel BJ; Blaney SM
J Clin Oncol; 2013 Aug; 31(24):3034-43. PubMed ID: 23857966
[TBL] [Abstract][Full Text] [Related]
30. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
Jeon SY; Lee NR; Yim CY
BMC Nephrol; 2019 Jan; 20(1):1. PubMed ID: 30606155
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
32. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Verweij J; Sleijfer S
Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
[TBL] [Abstract][Full Text] [Related]
33. Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature.
Karaağaç M; Eryılmaz MK
J Oncol Pharm Pract; 2020 Apr; 26(3):768-774. PubMed ID: 31547750
[TBL] [Abstract][Full Text] [Related]
34. Nanoparticle-based pazopanib shows promise in OA.
Kelsey R
Nat Rev Rheumatol; 2024 May; 20(5):253. PubMed ID: 38503892
[No Abstract] [Full Text] [Related]
35. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
Schulte B; Mohindra N; Milhem M; Attia S; Robinson S; Monga V; Hirbe AC; Oppelt P; Charlson J; Helenowski I; Abbinanti S; Cehic R; Okuno S; Van Tine BA; Agulnik M
Br J Cancer; 2021 Aug; 125(4):528-533. PubMed ID: 34050255
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.
Ferrero S; Leone Roberti Maggiore U; Aiello N; Barra F; Ditto A; Bogani G; Raspagliesi F; Lorusso D
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):881-889. PubMed ID: 28678537
[TBL] [Abstract][Full Text] [Related]
38. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
[TBL] [Abstract][Full Text] [Related]
39. Response to pazopanib in two pediatric patients with pretreated relapsing synovial sarcoma.
Casanova M; Basso E; Magni C; Bergamaschi L; Chiaravalli S; Carta R; Tirtei E; Massimino M; Fagioli F; Ferrari A
Tumori; 2017 Jan; 103(1):e1-e3. PubMed ID: 27647230
[TBL] [Abstract][Full Text] [Related]
40. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.
Abbas O; Shamseddin A; Temraz S; Haydar A
BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23436889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]